CHE (CHE) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving CHE (CHE) right now is VITAS hospice demand and aging demographics: An aging US population and rising acceptance of hospice care support steady demand for VITAS services. Revenue (TTM) is ~$2.5B. If that keeps playing out, the setup is favourable; the risk to it is vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. No one can predict where CHE trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive CHE (CHE) higher?
1. VITAS hospice demand and aging demographics
An aging US population and rising acceptance of hospice care support steady demand for VITAS services. VITAS grew net revenue roughly 3% year over year in Q1 2026 to about $420 million, and management has been expanding capacity and admissions. Because hospice is a defensive, non-discretionary service, this segment provides ballast against economic cycles.
2. Reduced Medicare Cap drag
VITAS has periodically faced Medicare Cap billing limitations that force refunds when payments exceed per-patient ceilings. Management projected the Cap headwind to fall sharply to roughly $9.5 million in 2026 from about $27.2 million in 2025, which supports higher realized VITAS revenue and margins if admissions and length-of-stay trends hold.
3. Roto-Rooter footprint and franchise buy-ins
Roto-Rooter is the dominant national brand in plumbing and drain services, giving it pricing power and brand recall competitors lack. Chemed continues to buy back independent franchise territories (adding markets serving millions of people in early 2026), converting franchise royalties into higher-margin company-owned revenue over time.
4. Strong cash generation and buybacks
Chemed converts earnings into substantial free cash flow (roughly $325 million after capex in 2025) with low debt, and consistently repurchases shares. This capital-return discipline steadily shrinks the share count and supports per-share earnings even when consolidated revenue grows only in the mid-single digits.
What could weigh on CHE?
VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. The hospice industry faces heavy regulatory oversight (Conditions of Participation, anti-kickback and false-claims rules, audits, and past MAC repayment demands), and VITAS disclosed a 2025 cyberattack exposing protected health information. Roto-Rooter is cyclical and weather-dependent, with recent softness in restoration demand and margin pressure, plus reliance on scarce licensed-plumber labor. The stock also trades at a premium multiple, so any disappointment on volumes or margins can drive sharp drawdowns, as seen after weaker quarters.
Where CHE trades today
A forecast starts from where the stock actually is. These are CHE's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for CHE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a CHE forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the CHE guide and whether CHE is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the CHE outlook
The bottom line: what is driving CHE (CHE) is VITAS hospice demand and aging demographics, with revenue (ttm) at ~$2.5B. If that keeps playing out the setup is favourable; the risk is vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. No one can predict the price, so treat any CHE forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around CHE with Walnut
Use CHE as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for CHE (CHE)?
+
No one can reliably predict where CHE will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push CHE higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive CHE higher?
+
The main growth drivers are VITAS hospice demand and aging demographics; Reduced Medicare Cap drag; Roto-Rooter footprint and franchise buy-ins. Whether they play out is the real question, not a guaranteed path.
What are the risks to CHE?
+
VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. The hospice industry faces heavy regulatory oversight (Conditions of Participation, anti-kickback and false-claims rules, audits, and past MAC repayment demands), and VITAS disclosed a 2025 cyberattack exposing protected health information. Roto-Rooter is cyclical and weather-dependent, with recent softness in restoration demand and margin pressure, plus reliance on scarce licensed-plumber labor. The stock also trades at a premium multiple, so any disappointment on volumes or margins can drive sharp drawdowns, as seen after weaker quarters.
Will CHE stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. CHE's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is CHE a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the CHE "is it a buy?" page for a framework. Walnut is not an investment adviser.
What could drive Chemed's results going forward?
+
Key drivers include VITAS admissions and length-of-stay trends, a smaller Medicare Cap billing drag in 2026, Roto-Rooter demand recovery and restoration margins, and continued franchise buy-ins. Reimbursement policy changes and weather-driven plumbing demand can swing results in either direction.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.